Login to Your Account

Revlimid Hits Target in Newly Diagnosed Myeloma Patients

By Catherine Shaffer
Staff Writer

Thursday, July 11, 2013
Celgene International Sarl's successful multiple myeloma drug, Revlimid (lenolidomide), met an important benchmark in newly diagnosed patients in a Phase III study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription